Safety assessments were evaluated as either evidence of disease worsening or adverse events.

In the EpiCeram group, 2 patients previously treated with potent topical steroids, experienced worsening of atopic dermatitis, interpreted as "rebound flares" associated with steroid use.

Otherwise, there were no serious adverse events from EpiCeram during the course of the study.

Home    |    Atopic Dermatitis    |    Pathophysiology    |    Therapy    |    Mechanism of Action    |    Clinical Study    |    E-Library    |    Q&A    |    Contact Us    |    Site Map